2026 Kite-Gilead Cell Therapy Innovation Program supports Stanford investigators’ early-stage preclinical and translational research to improve cell therapy safety, efficacy, and patient outcomes.
Funder: Stanford University
Due Dates (Anticipated): July 2027 (CE faculty PI waiver requests) | July 2027 (Pre-proposals)
Funding Amounts: $200,000 in direct research funding, plus applicable institutional indirect costs, for up to 18 months
Summary: Supports Stanford investigators’ early-stage preclinical and translational research to improve cell therapy safety, efficacy, and patient outcomes.
Key Information: Restricted to PI-eligible Stanford faculty and Clinician Educator faculty with an approved PI waiver.
The Kite-Gilead Cell Therapy Innovation Program supports Stanford investigator collaborations through the Stanford-Kite Strategic Alliance, established in November 2024. It funds innovative, early-stage preclinical and translational cell therapy research, with scientific expertise and guidance from Kite-Gilead. The goal is to advance promising projects into clinically sponsored research and create in-licensing and start-up opportunities that expand Kite-Gilead’s early-stage portfolio.
Research interests include therapeutic targets, T-cell activation pathways, mechanisms to avoid CAR T-cell exhaustion, and approaches to improve safety and efficacy. The program also supports correlative analysis of patient samples and exploration of non-cancer indications. Oncology priorities include patient stratification, toxicity management, T-cell fitness, and lymphodepletion strategies. Rheumatology and immunology interests include identifying lupus patients suitable for B-cell targeting and rare autoimmune disorders that could benefit from CAR T-cell therapies. These topics are illustrative, not exhaustive.